FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Poster Presentation

SLE, Sjögren’s and APS - etiology, pathogenesis and animal models

FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Genovese M, Sebba A, Rubbert-Roth A, et al

FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years

Annals of the Rheumatic Diseases 2013;72:A461.